Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: A multicenter study

被引:238
作者
Kobayashi, Hirotoshi
Mochizuki, Hidetaka
Sugihara, Kenichi
Morita, Takayuki
Kotake, Kenjiro
Teramoto, Tatsuo
Kameoka, Shingo
Saito, Yukio
Takahashi, Keiichi
Hase, Kazuo
Oya, Masatoshi
Maeda, Koutarou
Hirai, Takashi
Kameyama, Masao
Shirouzu, Kazuo
Muto, Tetsuichiro
机构
[1] Tokyo Med & Dent Univ, Dept Surg Oncol, Grad Sch, Bunkyo Ku, Tokyo 1138519, Japan
[2] Tokyo Med & Dent Univ, JSCCR Postsurg Surveillance Colorectal Canc, Study Grp, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Dept Surg 1, Natl Def Med Coll, Tokyo, Japan
[4] Hirosaki Univ, Dept Surg, Sch Med, Hirosaki, Aomori 036, Japan
[5] Tokyo Womens Med Univ, Dept Surg 2, Tokyo, Japan
[6] Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo, Japan
[7] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Aichi, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan
[9] Kurume Univ, Sch Med, Dept Surg, Tokyo, Japan
关键词
D O I
10.1016/j.surg.2006.07.020
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. The aim of this study was to clarify the characteristics of recurrence and the effectiveness Of surveillance tools after curative resection for colorectal cancer. Methods. We enrolled 5230 consecutive Patients (stage 1, 1367; stage 11, 1912; stage 111, 1951) who underwent curative resection at 14 hospitals from 1991 to 1996. All patients were followed up intensively, and their outcomes were investigated retrospectively. Results. Of the 5230 patients, 906 developed recurrence. The recurrence rates of stage I, II, and III cancers were 3.7%, 13.3%, and 30.8%, respectively (P < .0001). The curves of the cumulative appearance rate Of recurrence in stage II and Iff patients showed a rapid increase for the first 3 years. Recurrence after 5 years was less than 1% in each stage. Clinical visits combined with measurements of tumor markers detected the majority of recurrences except in the case of lung metastasis. In contrast, 43.4% of hepatic recurrences were detected by liver imaging, and 48.4% of pulmonary recurrences were noted by chest x-ray. The 5-year survival rates after primary colorectal surgery in patients who underwent resection for recurrence were better than in those without resection: 55% vs 11% in hepatic recurrence, 68% vs 13% in Pulmonary recurrence, and 48% vs 22% in local recurrence (all P < .001). Conclusion. It is useful to take these characteristics of recurrence into account in the management Of patients after curative resection for colorectal cancer and in the selling of clinical trial for follow-up after curative resection for colorectal cancer.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 20 条
[1]   Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen [J].
André, T ;
Bensmaine, MA ;
Louvet, C ;
François, E ;
Lucas, V ;
Desseigne, F ;
Beerblock, K ;
Bouché, O ;
Carola, E ;
Merrouche, Y ;
Morvan, F ;
Dupon-André, G ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3560-3568
[2]  
[Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002200
[3]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[4]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[5]   Follow-up of patients with curatively resected colorectal cancer: a practice guideline [J].
Figueredo, A ;
Rumble, RB ;
Maroun, J ;
Earle, CC ;
Cummings, B ;
McLeod, R ;
Zuraw, L ;
Zwaal, C .
BMC CANCER, 2003, 3 (1)
[6]   Follow-up of colorectal cancer patients after resection with curative intent - the GILDA trial [J].
Grossmann, EM ;
Johnson, FE ;
Virgo, KS ;
Longo, WE ;
Fossati, R .
SURGICAL ONCOLOGY-OXFORD, 2004, 13 (2-3) :119-124
[7]   Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer [J].
Guillem, JG ;
Chessin, DB ;
Cohen, AM ;
Shia, J ;
Mazumdar, M ;
Enker, W ;
Paty, PB ;
Weiser, MR ;
Klimstra, D ;
Saltz, L ;
Minsky, BD ;
Wong, WD .
ANNALS OF SURGERY, 2005, 241 (05) :829-838
[8]   Cancer statistics, 2004 [J].
Jemal, A ;
Tiwari, RC ;
Murray, T ;
Ghafoor, A ;
Samuels, A ;
Ward, E ;
Feuer, EJ ;
Thun, MJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29
[9]  
Kjeldsen BJ, 1997, BRIT J SURG, V84, P666
[10]   Changes in colorectal cancer during a 20-year period: An extended report from the multi-institutional registry of large bowel cancer, Japan [J].
Kotake, K ;
Honjo, S ;
Sugihara, K ;
Kato, T ;
Kodaira, S ;
Takahashi, T ;
Yasutomi, M ;
Muto, T ;
Koyama, Y .
DISEASES OF THE COLON & RECTUM, 2003, 46 (10) :S32-S43